Recent advances in the treatment of hereditary nephrolithiasis in children

References:

1 Spivacow FR,Negri AL,Del Valle EE,et al.Clinical and metabolic risk factor evaluation in young adults with kidney stones[J].Int Urol Nephrol,2010,42(2):471-475.DOI:10.1007/s11255-009-9623-0.
2 Hoppe B,Martin-Higueras C.Inherited conditions resulting in nephrolithiasis[J].Curr Opin Pediatri,2020,32(2):273-283.DOI:10.1097/MOP.0000000000000848.
3 Arrabal-Polo MA,Arias-Santiago S,de Haro-Mu?oz T,et al.Effects of aminobisphosphonates and thiazides in patients with osteopenia/osteoporosis,hypercalciuria,and recurring renal calcium lithiasis[J].Urology,2013,81(4):731-737.DOI:10.1016/j.urology.2012.12.013.
4 Hannan FM,Babinsky VN,Thakker RV.Disorders of the calcium-sensing receptor and partner proteins:insights into the molecular basis of calcium homeostasis[J].J Mol Endocrinol,2016,57(3):R127-R142.DOI:10.1530/JME-16-0124.
5 Gabriel SS,Belge H,Gassama A,et al.Bone marrow transplantation improves proximal tubule dysfunction in a mouse model of Dent disease[J].Kidney Int,2017,91(4):842-855.DOI:10.1016/j.kint.2016.11.016.
6 Strauss SB,Waltuch T,Bivin W,et al.Primary hyperoxaluria:spectrum of clinical and imaging findings[J].Pediatr Radiol,2017,47(1):96-103.DOI:10.1007/s00247-016-3723-7.
7 Weigert A,Hoppe B.Nephrolithiasis and nephrocalcinosis in childhood-risk factor-related current and future treatment options[J].Front Pediatr,2018,6:98.DOI:10.3389/fped.2018.00098.
8 Bergstralh EJ,Monico CG,Lieske JC,et al.Transplantation outcomes in primary hyperoxaluria[J].Am J Transplant,2010,10(11):2493-2501.DOI:10.1111/j.1600-6143.2010.03271.x.
9 Harambat J,Van Stralen KJ,Espinosa L,et al.Characteristics and outcomes of children with primary oxalosis requiring renal replacement therapy[J].Clin J Am Soc Nephrol,2012,7(3):458-465.DOI:10.2215/CJN.07430711.
10 Hoppe B.An update on primary hyperoxaluria[J].Nat Rev Nephrol,2012,8(8):467-475.DOI:10.1038/nrneph.2012.113.
11 Azcarate-Peril MA,Bruno-Bárcena JM,Hassan HM,et al.Transcriptional and functional analysis of oxalyl-coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes from Lactobacillus acidophilus[J].Appl Environ Microbiol,2006,72(3):1891-1899.DOI:10.1128/AEM.72.3.1891-1899.2006.
12 Ivanovski O,Drüeke TB.A new era in the treatment of calcium oxalate stones?[J] Kidney Int,2013,83:998-1000.DOI:10.1038/ki.2013.41.
13 Dirk L,Kymora BS.The Role of Bacteria in Urology[M]//Knight J,Holmes RP.Role of oxalobacter formigenes colonization in calcium oxalate kidney stone disease.Springer,Cham,2019:95-102.
14 Siener R,Bangen U,Sidhu H,et al.The role of oxalobacter formigenes colonization in calcium oxalate stone disease[J].Kidney Int,2013,83(6):1144-1149.DOI:10.1038/ki.2013.104.
15 Arvans D,Jung YC,Antonopoulos D,et al.Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells[J].J Am Soc Nephrol,2017,28(3):876-887.DOI:10.1681/asn.2016020132.
16 Hatch M,Freel RW.A human strain of oxalobacter (HC-1) promotes enteric oxalate secretion in the small intestine of mice and reduces urinary oxalate excretion[J].Urolithiasis,2013,41(5):379-384.DOI:10.1007/s00240-013-0601-8.
17 Hoppe B,Beck B,Gatter N,et al.Oxalobacter formigenes:a potential tool for the treatment of primary hyperoxaluria type 1[J].Kidney Int,2006,70(7):1305-1311.DOI:10.1038/sj.ki.5001707.
18 Hoppe B,Groothoff JW,Hulton SA,et al.Efficacy and safety of oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria[J].Nephrol Dial Transplant,2011,26(1):3609-3615.DOI:10.1093/ndt/gfr107.
19 Hoppe B,Niaudet P,Salomon R,et al.A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered oxalobacter formigenes to treat primary hyperoxaluria[J].Pediatr Nephrol,2017,32(5):781-790.DOI:10.1007/s00467-016-3553-8.
20 Burns Z,Knight J,Fargue S,et al.Future treatments for hyperoxaluria[J].Curr Opin Urol,2020,30(2):171-176.DOI:10.1097/MOU.0000000000000709.
21 Beck BB,Hoyer-Kuhn H,G?bel H,et al.Hyperoxaluria and systemic oxalosis:an update on current therapy and future directions[J].Expert Opin Investig Drugs,2013,22(1):117-129.DOI:10.1517/13543784.2013.741587.
22 Salido,Eduardo,Luis-Lima,et al.Glycolate oxidase is a safe and efficient target for substrate reduction therapy in a mouse model of primary hyperoxaluria type I[J].Mol Ther,2016,24(4):719-725.DOI:10.1038/mt.2015.224.
23 Kletzmayr A,Ivarsson ME,Leroux JC.Investigational therapies for primary hyperoxaluria[J].Bioconjug Chem,2020,31(7)1696-1707.DOI:10.1021/acs.bioconjchem.0c00268.
24 Sahota A,Tischfield JA,Goldfarb DS,et al.Cystinuria:genetic aspects,mouse models,and a new approach to therapy[J].Urolithiasis,2019,47(1):57-66.DOI:10.1007/s00240-018-1101-7.
25 Rimer JD,An ZH,Zhu NZ,et al.Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design[J].Science,2010,330(6002):337-341.DOI:10.1126/science.1191968.
26 Sahota A,Parihar JS,Capaccione KM,et al.Novel cystine ester mimics for the treatment of cystinuria-induced urolithiasis in a knockout mouse model[J].Urology,2014,84(5):1249.e9-1249.e15.DOI:10.1016/j.urology.2014.07.043.
27 Hu LQ,Yang YH,Aloysius H,et al.L-cystine diamides as L-cystine crystallization inhibitors for cystinuria[J].J Med Chem,2016,59(15):7293-7298.DOI:10.1021/acs.jmedchem.6b00647.
28 Poloni LN,Zhu ZN,Garcia-Vaázquez N,et al.Role of molecular recognition in L-cystine crystal growth inhibition[J].Cryst Growth Des,2017,17(5):2767-2781.DOI:10.1021/acs.cgd.7b00236.
29 Yang YH,Albanyan H,Lee S,et al.Design,synthesis,and evaluation of l-cystine diamides as l-cystine crystallization inhibitors for cystinuria[J].Bioorg Med Chem Lett,2018,28(8):1303-1308.DOI:10.1021/acs.jmedchem.6b00647.
30 Ng N,Kaur A,Shenoy M.Recurrent kidney stones in a child with Lesch-Nyhan syndrome:Questions[J].Pediatr Nephrol,2019,34(3):423-424.DOI:10.1007/s00467-018-4035-y.
31 Kubihal S,Goyal A,Singla R,et al.Urolithiasis due to hereditary xanthinuria type II:a long-term follow-up report[J].Indian Pediatr,2020,57(5):468-469.DOI:10.1007/s13312-020-1825-7.
32 Grases F,Costa-Bauza A,Roig J,et al.Xanthine urolithiasis:Inhibitors of xanthine crystallization[J].PLoS One,2018,13(8):e0198881.DOI:10.1371/journal.pone.0198881.
33 Chow K,Dixon J,Gilpin S,et al.Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones[J].Kidney Int,2004,65(5):1724-1730.DOI:10.1111/j.1523-1755.2004.00566.x.
34 Hoppe B,Kemper MJ.Diagnostic examination of the child with urolithiasis or nephrocalcinosis[J].Pediatr Nephrol,2010,25(3):403-413.DOI:10.1007/s00467-008-1073-x.
35 Skrzypczyk P,Paczyk-Tomaszewska M.Hypocitraturia:its importance as a factor in the development of urolithiasis[J]. Pediatria i Medycyna Rodzinna,2019,15(1):26-32.DOI:10.15557/PiMR.2019.0005.
36 Karsli O,Izol V,Aridogan IA,et al.Metabolic risk factors and the effect of metaphylaxis in pediatric stone disease with hypocitraturia[J].Urolithiasis,2013,41(1):9-13.DOI:10.1007/s00240-012-0539-2.
37 Abe H,Orita Y,Ando A,et al.Renal tubular acidosis[J].J Pediatr,2014,164(11):691-698.e1.DOI:10.1016/j.jpeds.2013.10.085.